MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-? Inhibitor MYMD-1® in Rheumatoid Arthritis
Medical Marijuana Program Connection
MARCH 20, 2023
BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the. Read More
Let's personalize your content